Thermo Fisher Scientific and Daiichi Sankyo to Co-Develop Global Companion Diagnostic for Patients with Non-Small Cell Lung Cancer June 23, 2020June 23, 2020 by / Share This.....LinkedinTwitterFacebookGoogleEmailAgreement centers on identifying HER2 gene mutations using Oncomine Dx Target Test Related News: Roche’s VENTANA PD-L1 (SP263) Assay receives FDA…Oncomine Dx Target Test Receives MHLW Approval as a…FDA Approves NGS-Based Companion Diagnostic for EGFR…US FDA grants Priority Review to Roche’s Tecentriq…Roche receives positive CHMP opinion for Gavreto®…US FDA approves Roche’s Tecentriq as adjuvant…Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window)
